# BrainU Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brainu-co

- Industry: Medical Devices & Equipment
- Headquarters: Cheongju-si, South Korea
- Website: www.kor.brainu.co.kr/
- Total disclosed funding: $3.4M
- Latest round: Series A (Aug 4, 2026)
- Investors on record: 3

## About

Based in South Korea, BrainU Co., Ltd. operates in the neurotechnology sector, focusing on developing innovative medical devices and healthcare products that utilize advanced electroencephalogram (EEG) technology.BrainU Co., Ltd. was founded in 2018 in Cheongju-si, South Korea, specializing in neurotechnology solutions. The company has completed a total of 3 deals, with its most recent funding round being a Series A, raising KRW 3 billion on March 31, 2026. The investors in this round included Industrial Bank of Korea and WONIK Investment Partners.BrainU specializes in neurotechnology, particularly through the development of medical devices and healthcare products that leverage electroencephalogram (EEG) technology. Their core offerings include the CAI and CAI+ devices, which measure the depth of anesthesia during surgical procedures by quantifying brain activity on a scale from 0 to 100. The CAI+ is noteworthy for being the world’s first animal-specific anesthesia depth measurement device, designed for veterinary use. Additionally, BrainU has developed the MENTALade wearable device that monitors mental health by assessing EEG data and providing customized solutions based on the user’s mental state. The ST1 device utilizes electrical and thermal stimulation to assist users with sleep disturbances. These products have attained certifications in multiple international markets, including South Korea and Europe, targeting healthcare institutions, veterinary clinics, and individual consumers looking for mental health and sleep management solutions.BrainU's revenue for the most recent year, 2025, was KRW 1,204,751.6. The company employs a revenue model that includes direct sales of medical devices and healthcare products to hospitals, veterinary clinics, and consumers, indicating a B2B and B2C transactional structure. Sales transactions are executed through direct purchases, partnerships with healthcare providers, and potential subscription models for software applications linked to their wearable devices. Flagship products such as the CAI and CAI+ generate revenue through their adoption in surgical settings, while the MENTALade and ST1 devices cater to the growing demand for consumer wellness products. The pricing structure for these products is based on their specialized technology and certifications, positioning them as premium offerings in the neurotech market.BrainU Co., Ltd. plans to leverage its recent Series A funding of KRW 3 billion raised in March 2026 to enhance product development and expand its market reach. The company is focused on designing new products aimed at improving mental health monitoring and sleep management. Additionally, BrainU intends to penetrate new geographic markets in North America and Europe by the end of 2027, capitalizing on increasing global demand for neurotechnology solutions.

## Funding rounds

- Series A, Aug 4, 2026, $1.4M — Tony Investment
- Series A, Mar 31, 2026, $2M — Industrial Bank of Korea, WONIK Investment Partners

## Investors

- Industrial Bank of Korea — Series A
- WONIK Investment Partners (https://capitalatlas.ai/funds/wonik-investment-partners) — Series A
- Tony Investment (https://capitalatlas.ai/funds/tony-investment) — Series A